Now showing items 1-2 of 2

    • A combined ULBP2 and SEMA5A expression signature as a prognostic and predictive biomarker for colon cancer 

      Demirkol, S.; Gomceli, I.; Isbilen, M.; Dayanc, B. E.; Tez, M.; Bostanci, E. B.; Turhan, N.; Akoglu, M.; Ozyerli, E.; Durdu, S.; Konu, O.; Nissan, A.; Gonen, M.; Gure, A. O. (Ivyspring International Publisher, 2017)
      Background: Prognostic biomarkers for cancer have the power to change the course of disease if they add value beyond known prognostic factors, if they can help shape treatment protocols, and if they are reliable. The aim ...
    • TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT 

      Hill, R.; Madureira, P. A.; Ferreira, B.; Baptista, I.; Machado, S.; Colaço, L.; Dos Santos, M.; Liu, N.; Dopazo, A.; Ugurel, S.; Adrienn, A.; Kiss-Toth, E.; Isbilen, M.; Gure, A. O.; Link, W. (Nature Publishing Group, 2017)
      Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. ...